The Food and Drug Administration has approved Lipfendra, the first oral PCSK9 inhibitor for treating high cholesterol, including a genetic form known as familial hypercholesterolemia. Manufactured by Merck, the once daily pill offers patients an alternative to the injectable versions of this drug class that have been available for years, and it is expected to reach pharmacies within the coming weeks. The approval targets a condition the American Heart Association estimates affects roughly one in four adults, a buildup of LDL cholesterol that can raise the risk of heart attack and stroke if left unmanaged.
How the pill works inside the body
Lipfendra works by blocking a liver protein called PCSK9, which normally breaks down the receptors responsible for clearing LDL cholesterol from the bloodstream. Cardiologists explain that liver cells rely on these receptors to grab LDL cholesterol out of circulation, and PCSK9 typically marks those receptors for destruction after each use. By binding to PCSK9 and preventing it from reaching the receptors, the drug allows more of them to recycle back to the cell surface and keep clearing cholesterol, mirroring the mechanism used by injectable PCSK9 inhibitors already on the market.
The evidence behind the approval
The FDA’s decision rested on two large randomized trials, CORALreef Lipids and CORALreef HeFH, which enrolled more than 3,200 adults with severe high cholesterol who were already on the maximum tolerated dose of statins. Across both trials, the drug lowered LDL cholesterol by approximately 56% to 59% compared with a placebo, with consistent results among patients both with and without the inherited form of the condition. Those figures place it well ahead of other oral non statin options, which typically produce more modest reductions.
How it compares with existing treatments
Before this approval, patients with familial hypercholesterolemia relied on a mix of statins, ezetimibe, bempedoic acid, apheresis and injectable PCSK9 inhibitors, each carrying its own tradeoffs. Statins remain the standard first line treatment but can cause muscle pain in some patients, while ezetimibe and bempedoic acid tend to produce smaller reductions in LDL cholesterol. Injectable PCSK9 inhibitors require self administered shots every few weeks or, in one case, twice yearly dosing, along with refrigerated storage, whereas the new pill can be stored at room temperature and taken daily without needles.
What this means for patients going forward
Physicians say the oral format could expand access for patients who are unwilling or unable to use injectable treatments, while also serving as an add on option for those already on statins who still need additional help reaching their cholesterol goals. The drug will carry a list price of about 300 dollars a month, notably less than the roughly 500 dollars often associated with comparable injectable options, though patients will still need to check with their insurance providers to determine actual out of pocket costs. Doctors describe the approval as a meaningful step toward personalizing cholesterol treatment for a wider range of patients.
